{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:31:50Z","timestamp":1793237510219,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271147"],"award-info":[{"award-number":["82271147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571287"],"award-info":[{"award-number":["82571287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271146"],"award-info":[{"award-number":["82271146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaip.2026.07.031","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:14:16Z","timestamp":1785341656000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics and Selected Upper- and Lower-Airway Outcomes in AERD Subgroups: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Zusheng","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1543-2629","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.07.031_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.anai.2023.05.016","article-title":"Aspirin-exacerbated respiratory disease: updates in the era of biologics","volume":"131","author":"Mullur","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12931-014-0100-7","article-title":"Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis\/nasal polyps with and without aspirin hypersensitivity","volume":"15","author":"Machado-Carvalho","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2026.07.031_bib3","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2023.03.015","article-title":"Mechanistic and clinical updates in AERD: 2021-2022","volume":"151","author":"Stevens","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0091-6749(96)70123-9","article-title":"Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes","volume":"98","author":"Stevenson","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","article-title":"Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps","volume":"155","author":"Kratchmarov","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.18176\/jiaci.1155","article-title":"A systematic review of the specific role of biological therapies in aspirin-exacerbated respiratory disease","volume":"36","author":"L\u00e1zaro-Sastre","year":"2026","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jaip.2026.07.031_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2026.07.031_bib11","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.07.031_bib12","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2026.07.031_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines, 1: introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaip.2026.07.031_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions","volume":"64","author":"Brozek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.07.031_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12874-018-0483-0","article-title":"Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review","volume":"18","author":"Weir","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2026.07.031_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2026.07.031_bib17","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.07.031_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2026.07.031_bib20","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.07.031_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2026.07.031_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/00034894251344426","article-title":"Omalizumab efficacy in chronic rhinosinusitis patients with recurrent nasal polyps: an open-label, single-center, randomized, controlled study","volume":"134","author":"Noeiaghdam","year":"2025","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2026.07.031_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.07.031_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.07.031_bib30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/alr.70090","article-title":"Early and sustained improvements in sense of smell with tezepelumab treatment in patients with chronic rhinosinusitis with nasal polyps (WAYPOINT)","volume":"16","author":"Mullol","year":"2026","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2026.07.031_bib32","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaip.2025.03.033","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR","volume":"13","author":"Laidlaw","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.07.031_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2026.07.031_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.07.031_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100776","article-title":"Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps","volume":"16","author":"Braid","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.07.031_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaip.2026.07.031_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/19458924231218037","article-title":"Validation of minimal clinically important difference (MCID) for University of Pennsylvania Smell Identification Test (UPSIT)","volume":"38","author":"Mahadev","year":"2024","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2026.07.031_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaci.2022.09.012","article-title":"Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: a hypothesis","volume":"151","author":"Picado","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib42","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib43","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib44","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.07.031_bib45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.07.031_bib46","article-title":"Chronic rhinosinusitis with nasal polyps successfully treated with tezepelumab after an inadequate response to dupilumab: a case report","volume":"17","author":"Wakasugi","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.07.031_bib47","article-title":"Tezepelumab improved chronic rhinosinusitis with nasal polyps in a patient with aspirin exacerbated respiratory disease","volume":"50","author":"Yamashita","year":"2024","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaip.2026.07.031_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/01926230600713475","article-title":"The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium","volume":"34","author":"Harkema","year":"2006","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jaip.2026.07.031_bib49","first-page":"1","article-title":"Local and systemic safety of intranasal corticosteroids","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.07.031_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2125.2001.01325.x","article-title":"Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"Br J Clin Pharmacol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826006136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826006136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:48:50Z","timestamp":1793234930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826006136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S2213219826006136"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.07.031","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and Selected Upper- and Lower-Airway Outcomes in AERD Subgroups: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}